Narcolepsy – Pipeline Review, H2 2011

Narcolepsy – Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Narcolepsy - Pipeline Review, H2 2011', provides an overview of the Narcolepsy therapeutic pipeline. This report provides information on the therapeutic development for Narcolepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Narcolepsy. 'Narcolepsy - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Narcolepsy.
• A review of the Narcolepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Narcolepsy pipeline on the basis of route of administration and molecule type.
• Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Narcolepsy.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Narcolepsy therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Narcolepsy Overview
Therapeutics Development
An Overview of Pipeline Products for Narcolepsy
Narcolepsy Therapeutics under Development by Companies
Narcolepsy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Narcolepsy Therapeutics – Products under Development by Companies
Narcolepsy Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Narcolepsy Therapeutics Development
Evotec Aktiengesellschaft
Arena Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc.
BIOPROJET SCR
Narcolepsy – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
APD916 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Pitolisant - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Biaxin - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
EVT501 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
BF2.649 + Modafinil - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
C-10291 - Drug Profile
  Product Description
  Mechanism of Action
  R&D Progress
Narcolepsy Therapeutics – Drug Profile Updates
Narcolepsy Therapeutics – Discontinued Products
Narcolepsy – Product Development Milestones
Narcolepsy – Product Development Milestones
Featured News & Press Releases
Apr 15, 2011: European Medicines Agency Recommends Interim Measures For Pandemrix
Jan 25, 2011: Cephalon Announces Positive Topline Results From Phase IV Study Of NUVIGIL In Shift Work Disorder
Dec 21, 2010: Jazz Receives US Patent For Sodium Oxybate
Oct 22, 2010: Cephalon Receives FDA Approval For Risk Evaluation And Mitigation Strategy Of NUVIGIL
Oct 20, 2010: Arena Announces Phase I Results For APD916 For Treatment Of Narcolepsy With Cataplexy
Oct 05, 2010: Jazz Announces Paragraph IV ANDA Filing For Xyrem
Mar 29, 2010: Cephalon Receives Complete Response Letter for NUVIGIL for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Narcolepsy, H2 2011
Products under Development for Narcolepsy – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Evotec Aktiengesellschaft, H2 2011
Arena Pharmaceuticals, Inc., H2 2011
Concert Pharmaceuticals, Inc., H2 2011
BIOPROJET SCR, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Narcolepsy Therapeutics – Drug Profile Updates
Narcolepsy Therapeutics – Discontinued Products

LIST OF FIGURES

Number of Products under Development for Narcolepsy, H2 2011
Products under Development for Narcolepsy – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011 Skip to top